O8Z3 Stock Overview
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sonoma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.15 |
| 52 Week High | US$1.40 |
| 52 Week Low | US$0.13 |
| Beta | 1.29 |
| 1 Month Change | 0% |
| 3 Month Change | 7.14% |
| 1 Year Change | n/a |
| 3 Year Change | -97.77% |
| 5 Year Change | -97.90% |
| Change since IPO | -99.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| O8Z3 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.5% |
| 1Y | n/a | -22.6% | 6.0% |
Return vs Industry: Insufficient data to determine how O8Z3 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how O8Z3 performed against the German Market.
Price Volatility
| O8Z3 volatility | |
|---|---|
| O8Z3 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: O8Z3 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine O8Z3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9 | Amy Trombly | www.sonomapharma.com |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product.
Sonoma Pharmaceuticals, Inc. Fundamentals Summary
| O8Z3 fundamental statistics | |
|---|---|
| Market cap | €2.32m |
| Earnings (TTM) | -€4.76m |
| Revenue (TTM) | €11.53m |
0.2x
P/S Ratio-0.5x
P/E RatioIs O8Z3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O8Z3 income statement (TTM) | |
|---|---|
| Revenue | US$12.31m |
| Cost of Revenue | US$7.79m |
| Gross Profit | US$4.52m |
| Other Expenses | US$9.59m |
| Earnings | -US$5.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 36.70% |
| Net Profit Margin | -41.23% |
| Debt/Equity Ratio | 0.7% |
How did O8Z3 perform over the long term?
See historical performance and comparison